Literature DB >> 19182475

Frontotemporal dementia: therapeutic interventions.

Mario F Mendez.   

Abstract

The management of frontotemporal dementia (FTD), a disorder characterized by varied behavioral symptoms, primarily involves the use of psychoactive medications. Although there are no approved treatments for the disorder, selective serontonin receptor inhibitors, such as sertraline, paroxetine, or fluoxetine, can decrease disinhibition-impulsivity, repetitive behaviors, and eating disorders in FTD. Low doses of trazodone or an atypical antipsychotic such as aripriprazole can also help manage significantly disturbed or agitated behavior. The acetylcholinesterase inhibitors used for patients with Alzheimer's disease have not had significant efficacy for patients with FTD, but memantine, another dementia medication, is under investigation for the treatment of this disorder. In addition to drug therapy, the nonpharmacological management of patients with FTD focuses on education, behavioral interventions, and care of the caregivers. Most recently, investigators have initiated steps toward rational drug therapy with the development of outcome measures for clinical drug trials in FTD and the characterization of treatment targets such tau protein or the TAR DNA-binding protein 43. This approach holds great promise for an eventual treatment for this devastating early-onset dementia. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182475     DOI: 10.1159/000197896

Source DB:  PubMed          Journal:  Front Neurol Neurosci        ISSN: 0300-5186


  29 in total

1.  When laughing is no joking matter.

Authors:  Roy Yaari; Helle Brand; James D Seward; Anna D Burke; Adam S Fleisher; Jan Dougherty; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Late-onset cinephilia and compulsive behaviors: harbingers of frontotemporal dementia.

Authors:  Andrea Slachevsky; Carlos Muñoz-Neira; Javier Nuñez-Huasaf; Theodore A Stern; Carl R Blesius; Alireza Atri
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Psychiatric conditions that can mimic early behavioral variant frontotemporal dementia: the importance of the new diagnostic criteria.

Authors:  Facundo Manes
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

Review 4.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

5.  Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.

Authors:  Jeffrey L Cummings; John Ringman; Karen Metz
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Treatment options for tauopathies.

Authors:  Tarik Karakaya; Fabian Fußer; David Prvulovic; Harald Hampel
Journal:  Curr Treat Options Neurol       Date:  2012-04       Impact factor: 3.598

7.  Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.

Authors:  Maria Carmela Tartaglia; Bei Hu; Kala Mehta; John Neuhaus; Kristine Yaffe; Bruce L Miller; Adam Boxer
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Apr-Jun       Impact factor: 2.703

8.  Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus.

Authors:  Stefan J Teipel; Wilhelm Flatz; Nibal Ackl; Michel Grothe; Ingo Kilimann; Arun L W Bokde; Lea Grinberg; Edson Amaro; Vanja Kljajevic; Eduardo Alho; Christina Knels; Anne Ebert; Helmut Heinsen; Adrian Danek
Journal:  Psychiatry Res       Date:  2013-12-06       Impact factor: 3.222

Review 9.  Diagnosis and management of behavioral issues in frontotemporal dementia.

Authors:  Masood Manoochehri; Edward D Huey
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

10.  Diagnosis and treatment of corticobasal degeneration.

Authors:  Melissa J Armstrong
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.